Loading...
•
Dec 31, 2024
Abbott Q4 2024 Earnings Report
Reported strong sales and earnings growth, achieving the upper end of initial guidance for 2024 and positioned for continued growth in 2025.
Key Takeaways
Abbott's Q4 2024 results showed strong momentum with sales growth and EPS growth reaching the highest of the year. The company achieved the upper end of its initial guidance ranges for 2024 and projects continued strong growth in 2025.
Fourth-quarter sales increased 7.2 percent on a reported basis and 10.1 percent on an organic basis, excluding COVID-19 testing-related sales.
GAAP diluted EPS was $5.27, and adjusted diluted EPS was $1.34, excluding specified items.
Full-year 2024 sales increased 4.6 percent on a reported basis and 9.6 percent on an organic basis, excluding COVID-19 testing-related sales.
Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%. Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales. Abbott projects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25 and first-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09.
Positive Outlook
- Full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.
- Full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.
- Full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25.
- First-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...